News and Announcements
Prescient Therapeutics Investor Presentation April 2016
- Published April 13, 2016 11:52AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
13th April 2016, ASX Announcement
Investment Summary: Why all the excitement about AML?
- Acute Myeloid Leukemia (AML) is an area of substantial unmet medical need.
– One of the worst survival rates of all cancers
– Standard of care unchanged for 40 years - A disease of intense interest for clinicans, pharma companies and investors
- Celator Pharmaceuticals (NASDAQ: CPXX) showed what can happen when enhancing the standard of care in AML
– Market cap recently surged from small cap to $780M
-Dr Jeff Lancet was the Principal Investigator on CPXX’s ground-breaking trial - PTX has successful Phase 1 trial in AML (conducted at Moffitt and MD Anderson)
To view the full article please click on the button below.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
